Evidence map›Paper›PMID 29965975›Full record

ArticlePloS one2018

Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.

Saleena Subaiya, Collins Tabu, James N'ganga, Abdulkadir Amin Awes, Kibet Sergon, Leonard Cosmas, Ashley Styczynski, Samson Thuo, Emmaculate Lebo, Reinhard Kaiser and 6 more

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Saleena SubaiyaGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Collins TabuNational Vaccines and Immunization Program, Ministry of Health, Nairobi, Kenya.
James N'gangaKenya National Bureau of Statistics, Nairobi, Kenya.
Abdulkadir Amin AwesKenya National Bureau of Statistics, Nairobi, Kenya.
Kibet SergonWorld Health Organization Country Office, Nairobi, Kenya.
Leonard CosmasWorld Health Organization Country Office, Nairobi, Kenya.
Ashley StyczynskiEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Samson ThuoNational Vaccines and Immunization Program, Ministry of Health, Nairobi, Kenya.
Emmaculate LeboGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Reinhard KaiserWorld Health Organization, Inter-country Support Team for Eastern and Southern Africa, Harare, Zimbabwe.
Robert PerryWorld Health Organization, Geneva, Switzerland.
Peter AdembaNational Vaccines and Immunization Program, Ministry of Health, Nairobi, Kenya.
Katrina KretsingerWorld Health Organization, Geneva, Switzerland.
Iheoma OnuekwusiWorld Health Organization Country Office, Nairobi, Kenya.
Howard GaryGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Heather M ScobieGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0002-5448-6275

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionTo achieve measles elimination, two doses of measles-containing vaccine (MCV) are provided through routine immunization services or vaccination campaigns. In May 2016, Kenya conducted a measles-rubella (MR) vaccination campaign targeting 19 million children aged 9 months-14 years, with a goal of achieving ≥95% coverage. We conducted a post-campaign cluster survey to estimate national coverage and classify coverage in Kenya's 47 counties.

methodsThe stratified multi-stage cluster survey included data from 20,011 children in 8,253 households sampled using the recently revised World Health Organization coverage survey methodology (2015). Point estimates and 95% confidence intervals (95% CI) of national campaign coverage were calculated, accounting for study design. County vaccination coverage was classified as 'pass,' 'fail,' or 'intermediate,' using one-sided hypothesis tests against a 95% threshold.

resultsEstimated national MR campaign coverage was 95% (95% CI: 94%-96%). Coverage differed significantly (p < 0.05) by child's school attendance, mother's education, household wealth, and other factors. In classifying coverage, 20 counties passed (≥95%), two failed (<95%), and 25 were intermediate (unable to classify either way). Reported campaign awareness among caretakers was 92%. After the 2016 MR campaign, an estimated 93% (95% CI: 92%-94%) of children aged 9 months to 14 years had received ≥2 MCV doses; 6% (95% CI: 6%-7%) had 1 MCV dose; and 0.7% (95% CI: 0.6%-0.9%) remained unvaccinated.

conclusionsKenya reached the MR campaign target of 95% vaccination coverage, representing a substantial achievement towards increasing population immunity. High campaign awareness reflected the comprehensive social mobilization strategy implemented in Kenya and supports the importance of including strong communications platforms in future vaccination campaigns. In counties with sub-optimal MR campaign coverage, further efforts are needed to increase MCV coverage to achieve the national goal of measles elimination by 2020.

Indexed as

AdolescentChildChild, PreschoolFemaleHumansImmunization ProgramsInfantKenyaMaleMeaslesMeasles VaccineRubellaRubella VaccineSurveys and QuestionnairesVaccinationWorld Health OrganizationMeasles VaccineRubella Vaccine

Identifiers

PMID29965975
PMCPMC6028100

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.